

August 2, 2022

Bill Chen  
Chief Executive Officer  
LAAA Merger Corp.  
667 Madison Avenue  
New York, NY 10065

Re: LAAA Merger Corp.  
Registration

Statement on Form S-4

Filed June 29, 2022  
File No. 333-265885

Dear Mr. Chen:

We have reviewed your registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments.

Registration Statement on Form S-4

Cover Page

1. Please provide more prominent disclosure on the cover page that you are requiring public shareholders who wish to redeem their ordinary shares to either tender their certificates to Lakeshore's transfer agent or deliver their shares to the transfer agent electronically two business days before the Extraordinary General Meeting. Please also provide prominent disclosure on the cover page and in the Q&A section that shareholders should allot at least two weeks to obtain physical certificates from the transfer agent. We note disclosure to this effect on page 60.

Bill Chen  
FirstName LastNameBill Chen  
LAAA Merger Corp.  
Comapany  
August NameLAAA Merger Corp.  
2, 2022

August  
Page 2 2, 2022 Page 2  
FirstName LastName

2. Please revise the disclosure in the third paragraph concerning the Minimum Cash Amount to clarify that ProSomnus can waive the condition and therefore there is no guarantee that the combined company will have some or all of the \$40 million immediately following the closing.

3. Please disclose here, or elsewhere as applicable, the Closing Net Indebtedness as of a recent date.

Questions and Answers About The Business Combination and the Extraordinary General Meeting

What happens if a substantial number of public shareholders vote in favor of

the business  
combination proposal and exercise their redemption, page 10

4. Revise your disclosure to show the potential impact of redemptions on the per share value of the shares owned by non-redeeming shareholders by including a sensitivity analysis showing a range of redemption scenarios, including minimum, maximum and multiple interim redemption levels.

Will Lakeshore enter into any financing arrangements in connection with the Business Combination?, page 10

5. Please highlight material differences in the terms and price of securities issued at the time of the IPO as compared to private placements conducted in connection with the business combination. Disclose if the SPAC's sponsors, directors, officers or their affiliates will participate in the private placement.

6. We note that you plan to enter into agreements with certain investors pursuant to which such investors will purchase convertible notes of PubCo with an aggregate principal funding equal to thirty million dollars in a private placement or placements to be consummated immediately prior to the consummation of the Business Combination. Revise the disclosure to discuss the key terms of any convertible securities and to disclose the potential impact of those securities on non-redeeming shareholders.

Summary of the Proxy Statement/Prospectus  
The Parties to the Business Combination  
Lakeshore Acquisition I Corp., page 19

7. Please identify the underwriters upon first usage.  
Post-Business Combination Ownership and Impact on the Public Float, page 21

8. Please disclose the sponsor and its affiliates' total potential ownership interest in the combined company, assuming exercise and conversion of all securities.  
Lock-up Agreement, page 23

9. Please identify the ProSomnus stockholders who are subject to the lock-up.

Bill Chen  
FirstName LastNameBill Chen  
LAAA Merger Corp.  
Comapany  
August NameLAAA Merger Corp.  
2, 2022

August  
Page 3 2, 2022 Page 3  
FirstName LastName  
Interests of Certain Persons in the Business Combination, page 26

10. Please confirm here and on page 90 that the conflicts of interest discussion highlights all material interests in the transaction held by the sponsor and the company's officers and directors. This could include fiduciary or contractual obligations to other entities as well as any interest in, or affiliation with, the target company. As currently drafted, you disclose only certain interests "among other things." In addition, please revise your disclosure to clarify how the board considered these conflicts in negotiating and recommending the business combination.

11. Please disclose the following risks here and on page 90: that the sponsor will benefit from the completion of a business combination and may be incentivized to complete an acquisition of a less favorable target company or on terms less favorable to shareholders rather than liquidate; the sponsor and its affiliates can earn a positive rate of return on their investment, even if other SPAC shareholders experience a negative rate of return in the post-business combination company;

that your Amended and Restated Certificate of Incorporation waived the corporate

opportunities doctrine.

Additionally, please disclose whether this waiver of the corporate opportunities doctrine

impacted your search for an acquisition target.

12. We note that your sponsor and certain members of your management are involved with

other SPACs, specifically Lakeshore Acquisition II Corp. Please disclose the existence of

any related interests or conflicting duties in this section and on page 90.

We are subject to inspection and market surveillance by the FDA to determine compliance with regulatory requirements . . ., page 52

13. With reference to the bracketed language on page 52, please revise to describe any FDA

warning letters, censures, or FDA audits.

Risks Related to the Business Combination, page 61

14. Disclose the material risks to unaffiliated investors presented by taking the company

public through a merger rather than an underwritten offering. These risks could include

the absence of due diligence conducted by an underwriter that would be subject to liability

for any material misstatements or omissions in a registration statement.

Lakeshore shareholders will experience immediate dilution as a consequence of the issuance of

PubCo Common Stock. . ., page 62

15. Please revise to disclose all possible sources and extent of dilution that shareholders who

elect not to redeem their shares may experience in connection with the business

combination. Provide disclosure of the impact of each significant source of dilution,

including the amount of equity held by founders, convertible securities, including warrants

Bill Chen

LAAA Merger Corp.

August 2, 2022

Page 4

retained by redeeming shareholders, at each of the redemption levels detailed in your

sensitivity analysis, including any needed assumptions, and ensure that this disclosure also

addresses the potential dilutive effects of the three tranches of earn-out shares.

Risks Related to Ownership of PubCo's Securities, page 63

16. Please highlight the material risks to public warrant holders, including those arising from

differences between private and public warrants. Clarify whether recent common stock

trading prices exceed the threshold that would allow the company to redeem public

warrants. Clearly explain the steps, if any, the company will take to notify all

shareholders, including beneficial owners, regarding when the warrants become eligible

for redemption.

17. Quantify the value of warrants, based on recent trading prices, that may be retained by

redeeming stockholders assuming maximum redemptions and identify any material

resulting risks.

PubCo's amended and restated certificate of incorporation will provide, subject to limited

exceptions, that the Court of Chancery. . ., page 66

18. Please revise this risk factor to disclose that there is a risk that your exclusive forum

provision may result in increased costs for investors to bring a claim.

Proposal No. 1 The Reincorporation Merger Proposal, page 74

19. With reference to Rule 14a-4(a)(3), please identify clearly and impartially each separate

matter intended to be acted upon. For instance, and without limitation, we note the supermajority voting provisions voting requirements discussed on page 79. For additional guidance, please refer to the interpretations available at:

<https://www.sec.gov/divisions/corpfin/guidance/exchange-act-rule-14a-4a3.htm>.  
Proposal No. 3 The Acquisition Merger Proposal  
Background of the Business Combination, page 92

20. Please revise the disclosure on page 94 to explain the discussions and negotiations held before and after the August 25 conference call. In this regard, it should be clear where each party stood with respect to valuation of ProSomnus when the parties ceased the transaction discussions for the first time. Discuss briefly some of the other alternatives that ProSomnus pursued following August 25.

FirstName LastNameBill Chen

21. Please disclose why Lakeshore and Prosomnus "decided to halt all conversations" on

Comapany NameLAAA

November 18, 2021Merger Corp.

and why they decided to resume the negotiations on February 25, 2022.

August 2, 2022 Page 4

FirstName LastName

Bill Chen

FirstName LastNameBill Chen

LAAA Merger Corp.

Comapany

August NameLAAA Merger Corp.

2, 2022

August

Page 5 2, 2022 Page 5

FirstName LastName

22. Please revise to describe the discussions and negotiations regarding the Minimum Cash

Condition, including the basis for establishing the condition at the \$40 million level. In this regard, we note that March 3 letter of intent established the condition at the \$30 million level.

23. Please revise the March 23 entry to explain the circumstances that necessitated the follow-

up. For instance, explain the reference to FDA Audit and explain the terms MDR and SOP to provide context to the discussions.

Lakeshore's Board of Director's Reasons for Approving the Business Combination, page 97

24. Please clarify which "independent director reviewed and considered" potential conflict of

interests during the business combination process. We note your disclosure on page 193 that you have three independent directors.

25. Please identify which "scientific studies indicat[ing] ProSomnus precision intraoral

devices as the most effective treatment for mild and moderate OSA" were reviewed by

Lakeshore's Board.

26. We note your disclosure on page 95 that ProSomnus's financial advisor provided

Lakeshore with projected annual financials through 2025; however, the projections

beginning on page 98 only extend through 2023. Accordingly, please revise to provide

the projections for 2024 and 2025. Also provide the 2018 and 2019 historical numbers.

27. Please revise to include any other financial projections provided to Lakeshore or its

advisors on or after August 4, 2021. In this regard, we note that the February 25 entry

indicates that ProSomnus's financial advisor presented an updated financial model to

Lakeshore.

Summary of ProSomnus Financial Analysis, page 98

28. We have difficulty in fully understanding the basis for your revenue

projections, which  
you expect to grow at a 67% CAGR during 2021 through 2023. Please  
provide the  
following information and revise your presentation accordingly.  
Provide a revenue breakdown by product for each year in the period  
2020 through  
2023 that distinguishes between legacy products and next  
generation products such as  
EVO and RPM  
Quantify the sales price per unit and unit volumes underlying your  
revenue  
projections for 2022 and 2023, consistent with related  
information for 2021 and  
2020 presented on page 156.  
Describe and quantify key factors underlying changes in sales  
price per unit and unit  
volumes for each year over the period 2020 through 2023.  
Quantify the impact of each revenue growth driver on your revenue  
projections for  
2022 and 2023, as well as the impact of next generation devices,  
EVO and RPM  
Explain your consideration of the sensitivity of these revenue  
projections to ongoing  
economic disruption in the US and EU markets.

Bill Chen  
FirstName LastName Bill Chen  
LAAA Merger Corp.  
Comapany  
August Name LAAA Merger Corp.  
2, 2022

August  
Page 6 2, 2022 Page 6  
FirstName LastName

Separately quantify the impact of each factor listed on page  
100 on your gross margin  
of 59% for 2022 and 65% for 2023.  
Provide information that would assist us in determining the  
sensitivity beyond 2023  
of reasonably likely changes in your financial metric, Revenue  
CAGR, which you  
state was 67% for period 2021 through 2023.  
29. We have difficulty in fully understanding your \$168 million enterprise  
value for  
ProSomnus. Please provide the following information and revise your  
presentation  
accordingly.  
Describe and quantify the components of enterprise value and  
reconcile the  
associated equity valuation to merger consideration of \$113  
million to be issued in  
common stock to the former shareholders of ProSomnus.  
You state that "Lakeshore's board of directors looked at valuation  
based on the  
forecast provided by ProSomnus management for FY2022-2023."  
Explain the nature  
of this valuation and how it was prepared, including the level of  
assistance provided  
to Lakeshore's Board of Directors by its investment banking firm,  
Craig -Hallum  
Capital Group.  
Explain and quantify how this valuation at \$168 million "resulted  
in a favorable  
comparison of ProSomnus."  
Describe and quantify the methods and assumptions underlying this  
valuation and  
explain whether earlier versions of this valuation based on  
different assumptions were  
considered by Lakeshore's Board of Directors.  
30. Please disclose when ProSomnus's management prepared its internal  
projections.  
U.S. Holders, page 116

31. Please have counsel provide a tax opinion addressing the material tax  
consequences that  
the Reincorporation and Acquisition Mergers will have on U.S. Holders  
who (i) hold  
shares in the combined company or (ii) redeem their Lakeshore shares.  
The tax opinion  
should address and express a conclusion for each material federal tax  
consequence. With  
reference to your disclosure on page 170 concerning Lakeshore s

likely status as a PFIC,  
please note that counsel's opinion should consider this PFIC status  
and also address  
whether the Reincorporation qualifies or does not qualify as a  
reorganization within the  
meaning of Section 368 of the Code. For additional guidance concerning  
assumptions and  
opinions subject to uncertainty, refer to Staff Legal Bulletin No. 19.  
Business of ProSomnus, page 123

32. Please identify which studies has shown that patients "strongly favor  
ProSomnus intraoral  
devices over CPAP and other legacy oral appliance therapy devices."  
Similarly, please  
identify which "sponsored studies reported mean nightly use of 7.2 and  
7.4 hours using  
ProSomnus devices" and which "independent studies found that patients  
treated with  
ProSomnus devices did not demonstrate the types of dental side effects  
commonly  
associated with CPAP and legacy oral appliances." Ensure that you  
provide information

Bill Chen  
FirstName LastNameBill Chen  
LAAA Merger Corp.  
Comapany  
August NameLAAA Merger Corp.  
2, 2022

August  
Page 7 2, 2022 Page 7  
FirstName LastName

about these studies in the business section, including the number of  
patients they have  
enrolled and their findings.  
Clinical Results and Studies, page 133

33. We note your disclosure that a "significant and growing body of  
published clinical  
evidence, including 653 patients evaluated across several independent  
and sponsored  
clinical investigations, supports the efficacy, compliance, safety,  
patient preference and  
symptom alleviation of ProSomnus therapy for patients with OSA." We  
also note that the  
clinical trials listed in this section do not include 653 total  
patients. Please disclose all  
clinical trials and their results or explain why you do not believe  
this information is  
material.  
Intellectual Property, page 137

34. For each material patent or patent family, please revise your  
disclosure to include the  
specific products or technologies to which the patents relate, the  
type of patent protection  
obtained (composition of matter, use or process), the jurisdiction of  
the patents, and the  
expiration year.

35. We note your disclosure on page 137 that you rely on invention  
assignment agreements to  
protect your intellectual property rights. Please file these  
agreements as exhibits to the  
registration statement or, alternatively, provide an analysis  
supporting your belief that  
such filing is not required. See Item 601 of Regulation S-K.  
Relatedly, please ensure that  
other material contracts related to ProSomnus's business, like  
license, supply, or customer  
agreements, are filed as exhibits to the registration statement.  
Going Concern and Management's Plans, page 157

36. Please revise here to discuss in greater detail Management's plans.  
In particular, revise to  
explain ProSomnus's current plans for the proceeds to be received in  
connection with the  
Business Combination, including the approximate amount intended to be  
used for each  
specific purpose. To the extent that the proceeds are not sufficient  
to carry out the  
strategies you outline on pages 127-128, then please disclose which  
areas will require

37. Please provide the following information related to your sale of  
intraoral devices and  
revise related information in your filing, accordingly.

Explain your sales and marketing process for targeting sleep  
dentists, sleep  
physicians, primary care providers and integrated healthcare  
service providers that  
possess the necessary OSA training under AASM practice  
guidelines.

Explain the nature and degree of product personalization that you  
are required to

Bill Chen

FirstName LastNameBill Chen

LAAA Merger Corp.

Comapany

August NameLAAA Merger Corp.

2, 2022

August

Page 8 2, 2022 Page 8

FirstName LastName

perform before and after the typical sale of an intraoral device.

Describe key terms for contracts with customers that purchase  
an intraoral device,

including provisions governing product performance, product  
defects

and returns/rebates.

Describe performance obligations associated with your sale of  
intraoral devices,

including any requirements to train sleep dentists, sleep  
physicians and other

providers, assist with their personalization of the device and  
address post-prescription

device performance and patient satisfaction.

Explain your consideration of the list price in determining  
transaction price. On

page 135, you state that "the list price for each product is  
based upon an analysis of

competitive prices, capacity dynamics, marginal manufacturing  
costs, incremental

value created to the customer and our business strategy." In this  
regard, explain how

you develop selling prices for your intraoral devices, how often  
these prices are

revised and the degree to which your pricing is effectively fixed  
or varies on a

customer-by-customer basis.

Expand your discussion of revenue recognition on page 161 to  
fully address the

requirements of ASC 606-10-50-1 through 50-3 and ASC  
606-10-50-17.

Expand your footnote disclosure addressing revenue recognition  
on pages F-12 and

F-44 to address all of the requirements of ASC 606-10-50,  
particularly ASC 606-10-

50-12 and ASC 606-10-50-18 through 50-21.

Current Directors and Executive Officers of Lakeshore, page 191

38. It appears that Bill Chen and H. David Sherman are current directors  
and officers

of Lakeshore Acquisition II Corp.; however, this business experience  
is not disclosed. If

these parties are still serving in these roles, please revise this  
section to disclose this

business experience. Refer to Item 401(e) of Regulation S-K.

Signatures, page II-6

39. Your current signature block states that Bill Chen is your President,  
Sole Director,

Principal Executive Officer, Principal Financial Officer and Principal  
Accounting

Officer. This conflicts with your disclosure on page 191 that Mr. Chen  
is currently

serving as your Chief Executive Officer and Chairman and that you have  
four

additional members of your board, including a different CFO. Please

reconcile. If necessary, ensure that your registration statement is signed by your principal executive officer, principal financial officer, controller or principal accounting officer, and by at least a majority of the board of directors.

General

40. We note that Craig Hallum and Roth Capital were underwriters for Lakeshore's initial public offering and served as advisers in connection with the proposed business combination transaction. We also note that Gordon Point Capital and Solomon Partners provided advisory services to ProSomnus. We further note press reports that certain Bill Chen LAAA Merger Corp. August 2, 2022 Page 9

financial advisors are ending their involvement in SPAC business combination transactions. Please tell us, with a view to disclosure, whether you have received notice from any of these institutions about them ceasing involvement in your transaction and how that may impact your deal or any deferred compensation owed to such company. In addition, disclose whether any other financial advisor served the parties, or advise. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

You may contact Franklin Wyman at 202-551-3660 or Kevin Kuhar at 202-551-3662 if you have questions regarding comments on the financial statements and related matters. Please contact Dillon Hagius at 202-551-7967 or Joe McCann at 202-551-6262 with any other questions.

FirstName LastNameBill Chen  
Corporation Finance  
Comapany NameLAAA Merger Corp.  
Sciences  
August 2, 2022 Page 9  
cc: Giovanni Caruso  
FirstName LastName

Sincerely,  
Division of  
Office of Life